玖玖资源网站,爆乳久久久,日韩精品乱码久久久蜜桃,精品呦国产一区二区三区,国产伦高清一区二区三区,sese一区二区,午夜精品福利一区二区三区,三级黄色网站久久免费

首頁
訂購/客服:400-666-5481

trans-Tranilast

    
99.9%

trans-Tranilast

源葉(MedMol)
S86288 一鍵復制產品信息
70806-55-2
C18H17NO5
327.33
貨號 規格 價格 上海 北京 武漢 南京 購買數量
S86288-5mg
99.9% ¥348.00 6 - - -
S86288-10mg
99.9% ¥586.00 7 - - -
S86288-25mg
99.9% ¥1020.00 6 - - -
S86288-50mg
99.9% ¥1615.00 5 - - -
S86288-100mg
99.9% ¥2890.00 5 - - -
S86288-200mg
≥98% ¥4200.00 貨期:2-3天 - - -
產品介紹 參考文獻 質檢證書(COA) 摩爾濃度計算器 相關產品

產品介紹

trans-Tranilast (trans-MK-341) is an antiallergic drug, used to treat bronchial asthma, allergic rhinitis and atopic dermatitis. Target: Angiotensin Receptor Tranilast has been approved in Japan and South Korea, since 1982, for the treatment of bronchial asthma, with indications for keloids and hypertrophic scar added in 1993. Tranilast is also used to treat asthma, autoimmune diseases, atopic and fibrotic pathologies, and can also inhibit angiogenesis. The antiproliferative properties of tranilast were found that tranilast elicited an inhibitory effect on fibroblast proliferation in vitro and also suppressed collagen production both in vitro and in vivo . Tranilast also reduced the release of chemical mediators from mast cells and suppressed hypersensitivity reactions. Three-week-old C57Bl/10 and mdx mice received tranilast (~300 mg/kg) in their food for 9 weeks, after which fibrosis was assessed through histological analyses, and functional properties of tibialis anterior muscles were assessed in situ and diaphragm muscle strips in vitro. Tranilast administration did not significantly alter the mass of any muscles in control or mdx mice, but it decreased fibrosis in the severely affected diaphragm muscle by 31% compared with untreated mdx mice (P< 0.05)

產品描述: trans-Tranilast (trans-MK-341) is an antiallergic drug, used to treat bronchial asthma, allergic rhinitis and atopic dermatitis. Target: Angiotensin Receptor Tranilast has been approved in Japan and South Korea, since 1982, for the treatment of bronchial asthma, with indications for keloids and hypertrophic scar added in 1993. Tranilast is also used to treat asthma, autoimmune diseases, atopic and fibrotic pathologies, and can also inhibit angiogenesis. The antiproliferative properties of tranilast were found that tranilast elicited an inhibitory effect on fibroblast proliferation in vitro and also suppressed collagen production both in vitro and in vivo . Tranilast also reduced the release of chemical mediators from mast cells and suppressed hypersensitivity reactions. Three-week-old C57Bl/10 and mdx mice received tranilast (~300 mg/kg) in their food for 9 weeks, after which fibrosis was assessed through histological analyses, and functional properties of tibialis anterior muscles were assessed in situ and diaphragm muscle strips in vitro. Tranilast administration did not significantly alter the mass of any muscles in control or mdx mice, but it decreased fibrosis in the severely affected diaphragm muscle by 31% compared with untreated mdx mice (P< 0.05)
靶點: RAAS
體內研究: Protodioscin (5 and 10 mg/kg) significantly improves glucose intolerance and reduced the levels of serum UA, BUN, Cr, TC and TG. Protodioscin significantly reduces renal concentrations of IL-1β, IL-6 and TNF-α by inhibiting the activation of nuclear factor-κB, c-Jun N-terminal kinase, p38 mitogen-activated protein kinase and extracellular signal-regulated kinase. Protodioscin ameliorates the death rate, inhibits the increase in neurological deficit scores and infarct volume, and reduces the apoptotic nerve cells induced by MCAO in rats. Protodioscin attenuates the change of relevant apoptins, suppresses the release of pro-inflammatory cytokines in serum and reverses the protein expression of NF-κB (in nucleus and cytoplasm) and IκBα (in cytoplasm) induced by MCAO in rats. Protodioscin (0.5?mg/kg, i.p.) increases the coagulation time by appr?50?% as compared to that of high-fat diet control rats. Protodioscin possesses a promising effect in lowering the blood levels of both lipoproteins, especially LDL, thus resulting in a high ratio of HDL/LDL
參考文獻: 1.Swiderski, K., et al., Tranilast administration reduces fibrosis and improves fatigue resistance in muscles of mdx dystrophic mice. Fibrogenesis Tissue Repair, 2014. 7(1): p. 1. 2.Rogosnitzky, M., R. Danks, and E. Kardash, Therapeutic potential of tranilast, an anti-allergy drug, in proliferative disorders. Anticancer Res, 2012. 32(7): p. 2471-8.
溶解性: Soluble  in  DMSO
保存條件: 2-8℃
配置溶液濃度參考:
1mg 5mg 10mg
1 mM 3.055 ml 15.275 ml 30.55 ml
5 mM 0.611 ml 3.055 ml 6.11 ml
10 mM 0.306 ml 1.528 ml 3.055 ml
50 mM 0.061 ml 0.306 ml 0.611 ml
注意: 部分產品我司僅能提供部分信息,我司不保證所提供信息的權威性,僅供客戶參考交流研究之用。

參考文獻

質檢證書(COA)

如何獲取質檢證書(COA)?
請輸入貨號和一個與之匹配的批號。
例如:
批號:JS298415 貨號:S20001-25g
在貨品標簽上如何找到貨號和批號?

摩爾濃度計算器

質量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)

=
×
×
主站蜘蛛池模板: 东丽区| 景洪市| 博野县| 平山县| 来安县| 舒城县| 六安市| 安龙县| 青浦区| 宣武区| 三穗县| 新昌县| 景谷| 峨边| 宣化县| 古浪县| 高台县| 垦利县| 卢湾区| 章丘市| 泗阳县| 德令哈市| 佛坪县| 绿春县| 阿合奇县| 罗江县| 沽源县| 容城县| 泾源县| 色达县| 中卫市| 耒阳市| 新邵县| 额尔古纳市| 辽源市| 达孜县| 麟游县| 恭城| 道真| 吴川市| 渑池县|